original articlessupportive careA phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
Key words
Cited by (0)
Data from this trial were previously presented in part at the Multinational Association of Supportive Care in Cancer International Symposium 2003, Berlin, Germany: Aapro MS, Bertoli LF, Lordick F, Bogdanova NV, Macciocchi A. Palonosetron is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC). Support Care Cancer 2003; 11: 291. Abstract A-17. Additional results were presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting, 2005, Las Vegas, Nevada, USA: Natale JJ and Cartmell AD. Improved efficacy of single-day regimen of palonosetron plus dexamethasone versus ondansetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting (CINV) [abstract and poster]. ASHP Midyear Clinical Meeting. 2005; 40: P690E.